The present systematic review aimed to identify prognostic values of blood-based biomarkers in patients treated with neoadjuvant chemotherapy (NAC) for urothelial carcinoma of the bladder (UCB).
The PubMed, Web of Science, and Scopus databases were searched in August 2020 according to the PRISMA statement.